From Globe Newswire.: 2024-05-15 18:00:00

The last patient’s last visit in the SIGNAL-AD Phase 2a trial of pepinemab for Alzheimer’s disease is set for early June 2024. Treatment with pepinemab aims to slow neurodegenerative disease progression. The drug blocks SEMA4D to prevent astrocyte activation and cognitive decline in Alzheimer’s and Huntington’s diseases. Pepinemab shows promise in protecting astrocyte functions and potentially enhancing current AD treatments. Financially, Vaccinex has seen positive growth with increased cash reserves and reduced losses in Q1 2024. Research and development expenses totaled $3.4 million, with general and administrative expenses at $1.8 million. Stockholders’ equity improved to $2.7 million as of March 31, 2024, partially due to warrant restructuring efforts. The company is working on a plan to maintain compliance with The Nasdaq Stock Market following a letter regarding equity standards. Vaccinex conducted a 1-for-14 reverse stock split on February 20, 2024, and is focused on developing pepinemab as a potential treatment for neurodegenerative diseases and cancer by blocking SEMA4D.



Read more at Globe Newswire.:: Vaccinex Reports First Quarter 2024 Financial Results and